Recombinant Human PLAU/uPA Protein，His

The study of PLAU (plasminogen activator, urokinase) and its recombinant protein, uPA (urokinase-type plasminogen activator), is significant in the field of biochemistry and medical research due to its crucial role in fibrinolysis and tissue remodeling. UPA is a serine protease that converts plasminogen into plasmin, initiating the degradation of fibrin in blood clots, which is vital for normal hemostasis and wound healing. Dysregulation of uPA is implicated in various pathological conditions, including cancer metastasis, where increased uPA activity is associated with tumor invasion and poor prognosis. Research into the recombinant expression of uPA has enabled the production of this protein for therapeutic and diagnostic applications. Recombinant uPA can be utilized in targeted therapies for thrombotic disorders, as well as in understanding its mechanisms in cancer progression. The ability to produce uPA in a controlled manner through recombinant techniques enhances the potential for developing novel treatments and improving patient outcomes. Furthermore, studies assessing the interactions of uPA with other proteins in the plasminogen activation system continue to provide insights into its biological functions and therapeutic potential, making it a focal point of ongoing research in both vascular biology and oncology.